Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Cyclic peptide deacetylase inhibitor
What ifWhat if the histone deacetylase inhibitor is romidepsin while gemcitabine remains the other active component?
Claim language“amount of (E)-N-hydroxy-3-(1-(phenylsulfonyl)-indolin-5-yl)-acrylamide”
Intracellular reduction of the romidepsin disulfide exposes a thiol that binds catalytic zinc in class I histone deacetylases. Enzyme inhibition increases histone acetylation while gemcitabine metabolites interfere with DNA synthesis.
1.1Benzamide deacetylase inhibitor
What ifWhat if the histone deacetylase inhibitor is entinostat while gemcitabine remains the other active component?
Claim language“amount of (E)-N-hydroxy-3-(1-(phenylsulfonyl)-indolin-5-yl)-acrylamide”
The ortho-amino benzamide group of entinostat binds catalytic zinc in class I histone deacetylases and reduces histone deacetylation. Gemcitabine supplies a separate mechanism through intracellular metabolites that inhibit ribonucleotide reductase and disrupt DNA chain extension.
1.2Topoisomerase I inhibition
What ifWhat if irinotecan supplies the DNA-directed activity alongside the indoline hydroxamate?
Claim language“amount of gemcitabine”
Carboxylesterases convert irinotecan to an active metabolite that stabilizes complexes between topoisomerase I and cleaved DNA. Replication forks encounter these complexes and generate DNA damage.
1.2Platinum DNA adduct formation
What ifWhat if oxaliplatin supplies the DNA-directed activity alongside the indoline hydroxamate?
Claim language“amount of gemcitabine”
Oxaliplatin forms reactive platinum species that bind DNA bases and produce predominantly intrastrand adducts. These adducts distort the DNA helix and impede replication and transcription.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Other field of use
Paired drug testing in veterinary oncology
Canine mammary tumor organoids grow in a three-dimensional extracellular matrix in a multiwell plate. The phenylsulfonyl indoline hydroxamate and gemcitabine are added together to the culture medium in test wells. Matched wells receive either agent alone or vehicle, and an ATP luminescence assay measures viability after exposure.
Component substitution
Cytarabine as the nucleoside analog
Cytarabine replaces gemcitabine as the nucleoside analog in a cultured tumor cell assay. The phenylsulfonyl indoline hydroxamate and cytarabine are added to the same wells at independently varied concentrations. Matched single-agent dilution series and vehicle controls provide reference measurements for the viability readout.
Parameter or scale variation
Staggered exposure in tumor cell cultures
Tumor cells are seeded in a 96-well plate and exposed to the phenylsulfonyl indoline hydroxamate at hour 0. Gemcitabine is added to the same wells at hour 6, and both agents remain in the medium until viability is measured at hour 72. Parallel wells receive both agents at hour 0, either agent alone on its corresponding schedule, or vehicle.
Two dimensional concentration matrix in microwells
A 384-well plate holds tumor cells and a six-by-six matrix of the phenylsulfonyl indoline hydroxamate and gemcitabine. Each agent occupies one axis, with five nonzero concentrations separated by threefold dilution steps and one zero-concentration level. Each concentration pair occupies three wells, and the two zero-concentration axes supply single-agent and vehicle controls. A plate reader records a viability signal from each well after 72 hours.
Combination with existing systems
Combined exposure in a perfused tumor chip
A microfluidic chip holds a tumor spheroid in a hydrogel chamber next to a perfusion channel. Two syringe pumps deliver media containing the phenylsulfonyl indoline hydroxamate and gemcitabine through a mixing junction upstream of the chamber. The mixed stream flows past the hydrogel, and fluorescence microscopy measures live and dead cells within the spheroid.
Automated or data-driven variant
Automated imaging of paired drug responses
A liquid-handling robot dispenses the phenylsulfonyl indoline hydroxamate and gemcitabine into seeded wells according to a plate map that includes paired treatments, single-agent controls, and vehicle controls. An incubated microscope captures images from the same fields before dispensing and every 12 hours for 72 hours. Image analysis software segments nuclei, counts them in each field, and reports per-well changes from baseline alongside the matched control measurements.
Specific version of a part
Crystalline parent compound capsules
A hard capsule contains a measured mass of the crystalline parent compound blended with microcrystalline cellulose and a disintegrant. The capsule shell opens in gastrointestinal fluid, and the fill disperses to expose the drug particles to the fluid.
Micronized oral drug suspension
Micronized particles of the parent compound disperse in water with a wetting agent and a cellulose-based suspending agent. Agitation redistributes settled particles before a measured volume is withdrawn to deliver the specified mass of active ingredient.
Freeze-dried gemcitabine injection
A sterile vial contains freeze-dried gemcitabine hydrochloride labeled by its gemcitabine content. Sterile sodium chloride solution reconstitutes the powder, and a measured volume is diluted for intravenous infusion.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1a therapeutically effective amount of (E)-N-hydroxy-3-(1-(phenylsulfonyl)-indolin-5-yl)-acrylamide or a pharmaceutically acceptable salt, ester, and/or solvate thereof; and
1.2a therapeutically effective amount of gemcitabine.
In one embodiment, the kit comprises two containers: (a) a first container containing an unit dosage form of a liposomal platinum complex, and (b) a second container containing a unit dosage form of gemcitabine or a pharmaceutically acceptable salt thereof, effective to treat cancer.
A · US 2008/0026045 A1 · ¶ 158
DHA-dFdC showed potent and broad spectrum antitumor activity against NCI-60 DTP human tumor cell lines and was significantly more effective than the molar equivalent dose of gemcitabine in controlling pancreatic tumor growth in several mouse models of pancreatic cancer, including a genetically engineered mouse model that spontanouesly develop pancreatic tumors resembling human pancreatic ductal adenocarcinoma (PDA) and athymic mice with orthotopically implanted human pancreat
B · US 2020/0384007 A1 · ¶ 5
An empty cell means only that no passage was reproduced there.
Statements in these documents
Thus, there is a significant need in the art for novel compounds, compositions, and methods that are useful for treating cancer with improved therapeutic indices.
A · US 2008/0026045 A1 · ¶ 6
The present invention relates to combination therapies comprising gemcitabine and a liposomal platinum complex, pharmaceutical compositions comprising gemcitabine and a liposomal platinum complex, and methods for treating cancer comprising administering a combination of gemcitabine and a liposomal platinum complex.
A · US 2008/0026045 A1 · ¶ 1
As such, there is a need in the art for delivery vehicles which can deliver a wide array of compounds, including hydrophobic and/or lipophilic compounds.
B · US 2020/0384007 A1 · ¶ 4
The nanoparticles are generally capable of controlled and sustained release of such beneficial agents, delivery of agents to desirable tissues such as tumors, and can generally increase the aqueous solubility and bioavailability of agents, thereby stabilizing and increasing the effective amount of an agent used in an administered formulation.
B · US 2020/0384007 A1 · ¶ 3
Cite aspatent.fyi, US 2026/0355155 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355155/, SHA-256 29bebc985bb57c44e7415b31ec59fed1f399cf8590fb0a1e4c569c433f5393de